Program
Phentolamine
Also written as “Phentolamine Ophthalmic Solution 0.75%”, “Phentolamine Mesylate Ophthalmic Solution 1%” and “Phentolamine Mesylate (NV-101)”.
Its studies are mostly in Mydriasis · Hypesthesia · Presbyopia · Vitamin A Deficiency · Glaucoma, Open-Angle, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Opus Genetics | 131 open or running | phase 3since Nov 2, 2020 | May 18, 2012 | Aug 2027phase 3 · NCT07140783 |
| Novalar Pharmaceuticals | 40 open or running | phase 3since Mar 30, 2006 | Sep 8, 2005 | none ahead |
| Novocol Pharmaceutical of Canada | 10 open or running | phase 4since Nov 11, 2011 | Nov 11, 2011 | none ahead |
Also a collaborator on its studies: Viatris.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 3 studies since Sep 8, 2005.
- Mar 30, 2006Phase 2 study in HypesthesiaNovalar Pharmaceuticals · NCT00309322 · 150 enrolled · United States
- Nov 11, 2011Novocol Pharmaceutical of Canada's first study: phase 4 study in Dental AnesthesiaNew to Novocol Pharmaceutical of CanadaNovocol Pharmaceutical of Canada · NCT01474382 · 150 enrolled · United States
- May 18, 2012Opus Genetics's first study: phase 2 study in Night Vision ComplaintsNew to Opus GeneticsOpus Genetics · NCT01703559 · 60 enrolled · United States
- May 21, 2019Phase 2 study in Glaucoma, Open-AngleOpus Genetics · NCT03960866 · 39 enrolled · United States
- Jun 28, 2019Phase 2 study in Decrease in Night VisionOpus Genetics · NCT04004507 · 24 enrolled · United States
- Jul 11, 2019Phase 2 study in MydriasisOpus Genetics · NCT04024891 · 32 enrolled · United States
- Nov 2, 20202 phase 3 studiesOpus Genetics · NCT04620213, NCT04638660
- Dec 15, 2020Phase 2 study in PresbyopiaOpus Genetics · NCT04675151 · 150 enrolled · United States
- Nov 16, 2021Phase 3 study in MydriasisOpus Genetics · NCT05134974 · 368 enrolled · United States
- Dec 16, 2021Phase 3 study in MydriasisOpus Genetics · NCT05223478 · 23 enrolled · United States
- Dec 2, 2022Phase 3 study in PresbyopiaOpus Genetics · NCT05646719 · 333 enrolled · United States
- Apr 1, 2024Phase 3 study in Vitamin A DeficiencyOpus Genetics · NCT06349759 · 200 enrolled · United States
- Aug 5, 2024Phase 3 study in PresbyopiaOpus Genetics · NCT06542497 · 569 enrolled · United States
- Aug 22, 2025Phase 3 study in Vitamin A DeficiencyOpus Genetics · NCT07140783 · 580 planned · United States
Ahead
- Aug 2027Primary completion: phase 3 study in Vitamin A DeficiencyOpus Genetics · NCT07140783
TargetBeta
“Adrenergic receptor alpha antagonist”ChEMBL 37, by rule
Other programs on the same 6 targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Oxymetazolinerule | AbbVie | phase 4 | 20 |
| Epinephrinerule | nasus-pharma | phase 4 | 17 |
Studies
All 18 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07140783Vitamin A Deficiency · United States | 3 | Recruiting | Opus Genetics | Aug 2027 | 580 |
| NCT06542497Presbyopia · United States | 3 | Completed | Opus Genetics | Apr 3, 2025 | 569 |
| NCT06349759Vitamin A Deficiency · United States | 3 | Completed | Opus Genetics | Apr 17, 2025 | 200 |
| NCT05646719Presbyopia · United States | 3 | Completed | Opus Genetics | Oct 11, 2023 | 333 |
| NCT05223478Mydriasis · United States | 3 | Completed | Opus Genetics | Apr 18, 2022 | 23 |
| NCT05134974Mydriasis · United States | 3 | Completed | Opus Genetics | Mar 18, 2022 | 368 |
| NCT04675151Presbyopia · United States | 2 | Completed | Opus Genetics | May 17, 2021 | 150 |
| NCT04638660Dim Light Vision Disturbances · United States | 3 | Completed | Opus Genetics | May 19, 2022 | 144 |
| NCT04620213Mydriasis · United States | 3 | Completed | Opus Genetics | Dec 23, 2020 | 185 |
| NCT04024891Mydriasis · United States | 2 | Completed | Opus Genetics | Sep 17, 2019 | 32 |
| NCT04004507Decrease in Night Vision · United States | 2 | Completed | Opus Genetics | Oct 2007 | 24 |
| NCT03960866Glaucoma, Open-Angle · United States | 2 | Completed | Opus Genetics | Sep 11, 2019 | 39 |
| NCT01703559Night Vision Complaints · United States | 2 | Completed | Opus Genetics | Apr 16, 2012 | 60 |
| NCT01474382Dental Anesthesia · United States | 4 | Completed | Novocol Pharmaceutical of Canada | Aug 2014 | 150 |
| NCT00309361Hypesthesia · United States | 3 | Completed | Novalar Pharmaceuticals | 240 | |
| NCT00309335Hypesthesia · United States | 3 | Completed | Novalar Pharmaceuticals | 240 | |
| NCT00309322Hypesthesia · United States | 2 | Completed | Novalar Pharmaceuticals | 150 | |
| NCT00154167Hypesthesia · United States | 2 | Completed | Novalar Pharmaceuticals | 122 |
How it is read
Names in the registry
- “Phentolamine Ophthalmic Solution 0.75%”, 5 entries
- “Phentolamine Mesylate Ophthalmic Solution 1%”, 3 entries
- “Phentolamine Mesylate (NV-101)”, 3 entries
- “Phentolamine Opthalmic Solution 0.75%”, 1 entry
- “Phentolamine Mesylate Ophthalmic Solution 1.0%”, 1 entry
Conditions, from the studies’ own filings
- Mydriasis, 4 studies
- Hypesthesia, 4 studies
- Presbyopia, 3 studies
- Vitamin A Deficiency, 2 studies
- Glaucoma, Open-Angle, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.